ANIX · Anixa Biosciences Inc
$3.59
-0.12 (-3.23%)
At close · Aug 20
Market Cap
$122.14M
Shares
34.02M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.59
Open$3.69
Day$3.55–3.71
52W close$2.35–5.22
Avg vol 30d246K
Short int1.1M · 3.2% float · 3.7d
Short vol39%
DataJan 2020–Aug 2026
Filing10-Q · Jun 10
Up next
FQ4-26 quarter ends
~Oct 31, 2026
Est
filed Jun 10, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+12%
above
Price vs 50-day avg
+13%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
43%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−4%
trailing
6-month return
+20%
trailing
YTD return
+15%
this year
Relative strength
+9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+2% holders QoQ · +9 funds added
Insider flow
Accumulating
Net +$199.8K over 90 days · 0% sells
Short interest
Rising
3.21% of float · ▲ +26.5% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
63 holders — mid 3-yr range
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
0%
Y/Y
EPS growth
+13%
Y/Y
Free cash flow
$-7.2M
Balance sheet
$873.8K
net cash
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
6.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+12%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
43%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
+2% holders QoQ · +9 funds added
Insider flow
Accumulating
Net +$199.8K over 90 days · 0% sells
Short interest
Rising
3.21% of float · ▲ +26.5% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
63 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $4 · 43%
Range high $5
vs 200-day avg +12%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANIX
this stock
Anixa Biosciences Inc
|
$122.14M | +15.1% | +0.0% | — | 3.2% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANIX | +12.2% | -4.3% | +20.5% | +5.0% | +15.1% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +14.2% | -7.6% | +9.3% | +2.9% | +3.2% |
Key facts
CIK
715446
CUSIP
03528H109
13F (30d)
60 filings
60 filers
Visit website
Investor relations